PROMETHEUS BIOSCIENCES, INC. Research and Development Expense
PROMETHEUS BIOSCIENCES, INC. reported Research and Development Expense of $36.42 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2023-05-09
- PROMETHEUS BIOSCIENCES, INC. research and development expense for the quarter ending 2023-03-31 was $36.42M, a 30.39% increase year-over-year.
- PROMETHEUS BIOSCIENCES, INC. research and development expense for the quarter ending 2022-12-31 was $29.94M, a 27.07% increase year-over-year.
- PROMETHEUS BIOSCIENCES, INC. research and development expense for the quarter ending 2022-09-30 was $29.08M, a 65.68% increase year-over-year.
- PROMETHEUS BIOSCIENCES, INC. research and development expense for the quarter ending 2022-06-30 was $25.92M, a 91.22% increase year-over-year.
- PROMETHEUS BIOSCIENCES, INC. research and development expense for fiscal 2022 was $112.85M, a 80.77% increase from fiscal 2021.
- PROMETHEUS BIOSCIENCES, INC. research and development expense for fiscal 2021 was $62.43M, a 226.04% increase from fiscal 2020.
- PROMETHEUS BIOSCIENCES, INC. research and development expense for fiscal 2020 was $19.15M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2023-03-31 | $36.42M 10-Q · filed 2023-05-09 | $66.36M derived: sum of 2 quarters · filed 2023-05-09 | $95.44M derived: sum of 3 quarters · filed 2023-05-09 | $121.36M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | $29.94M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $59.02M derived: sum of 2 quarters · filed 2023-02-28 | $84.94M derived: sum of 3 quarters · filed 2023-02-28 | $112.85M 10-K · filed 2023-02-28 |
| 2022-09-30 | $29.08M 10-Q · filed 2022-11-09 | $55.00M derived: sum of 2 quarters · filed 2022-11-09 | $82.91M 10-Q · filed 2022-11-09 | $106.49M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-06-30 | $25.92M 10-Q · filed 2022-08-11 | $53.85M 10-Q · filed 2022-08-11 | $77.41M derived: sum of 3 quarters · filed 2023-05-09 | $94.96M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-03-31 | $27.93M 10-Q · filed 2023-05-09 | $51.49M derived: sum of 2 quarters · filed 2023-05-09 | $69.05M derived: sum of 3 quarters · filed 2023-05-09 | $82.60M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $23.56M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $41.12M derived: sum of 2 quarters · filed 2023-02-28 | $54.67M derived: sum of 3 quarters · filed 2023-02-28 | $62.43M 10-K · filed 2023-02-28 |
| 2021-09-30 | $17.55M 10-Q · filed 2022-11-09 | $31.11M derived: sum of 2 quarters · filed 2022-11-09 | $38.86M 10-Q · filed 2022-11-09 | $44.17M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $13.55M 10-Q · filed 2022-08-11 | $21.31M 10-Q · filed 2022-08-11 | $26.62M derived: sum of 3 quarters · filed 2023-02-28 | $31.27M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $7.76M 10-Q · filed 2022-05-12 | $13.06M derived: sum of 2 quarters · filed 2023-02-28 | $17.72M derived: sum of 3 quarters · filed 2023-02-28 | $22.64M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $5.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $9.96M derived: sum of 2 quarters · filed 2023-02-28 | $14.88M derived: sum of 3 quarters · filed 2023-02-28 | $19.15M 10-K · filed 2023-02-28 |
| 2020-09-30 | $4.65M 10-Q · filed 2021-11-12 | $9.57M derived: sum of 2 quarters · filed 2021-11-12 | $13.84M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $4.92M 10-Q · filed 2021-08-11 | $9.19M 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | $4.26M 10-Q · filed 2021-05-13 |